Trial Profile

A global multi-center phase-II clinical trial of Oligomannate in the treatment of patients with early-stage Parkinson's disease (PD)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Jan 2022 New trial record
16 Jan 2022 According to Green Valley (Shanghai) Pharmaceuticals media release, received the letter from the US Food and Drug Administration (FDA) on the Investigational New Drug (IND) application for the global multi-center phase-II clinical trial of Oligomannate. The letter indicated the "Study May Proceed" with the proposed clinical investigation in the treatment of patients with early-stage Parkinson's disease.The IND effective date is December 16, 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com